Introduction
============

Tuberculosis (TB) remains one of the deadliest infectious diseases around the world. According to the World Health Organization, an estimated 10.4 million people developed TB, 1.4 million died from the disease in 2015, and an additional 0.4 million deaths resulted from TB disease among people living with HIV.[@b1-idr-11-431] The emergence and spread of multidrug-resistant TB (MDR-TB) with 3.3% of newly diagnosed TB cases worldwide, which was associated with poor treatment outcomes, aggravated the burden of TB treatment in many regions of the world.[@b2-idr-11-431] When it came to previously treated TB cases, 20% were identified as MDR-TB.[@b1-idr-11-431] However, the understanding of the interaction among various drug resistances in TB is quite poor.

Epistasis refers to the phenomenon of phenotypic effect exerted by one gene (locus) over another leading to the fact that epistatic mutations have different effects in combination than individually.[@b3-idr-11-431] Acting as the primary factor in molecular evolution, epistasis has been revealed in many processes.[@b4-idr-11-431] Recently, epistasis was reported as an important evolutionary force for the emergence of multidrug-resistant bacteria.[@b5-idr-11-431],[@b6-idr-11-431] In mycobacteria, resistance to rifampicin (RIF) and ofloxacin was reported to be affected by epistasis, in which different combinations of mutations in drug-resistant genes resulted in the varying degree of loss in fitness.[@b7-idr-11-431] However, a more generalized epistatic interaction in mutations conferring resistance to other anti-TB drugs remains unknown.

Streptomycin (STR) was first applied in clinical treatment for TB in 1946,[@b8-idr-11-431] although its use was reduced gradually in western countries due to its strong side effects and emergence of drug resistance. Nonetheless, in most developing countries, STR has been used as one of the first-line anti-TB drugs up to date, which induced serious STR resistance in these countries.[@b9-idr-11-431] Fluoroquinolones (FLQ), as an important second-line anti-TB drug, are critical to the treatment of MDR-TB.[@b10-idr-11-431] With the development of FLQ resistance, MDR-TB may progressively lead to the emergence of extensively drug-resistant (XDR), even totally drug-resistant (TDR) TB.[@b2-idr-11-431] During the treatment of MDR-TB cases, STR is usually prescribed in combination with FLQ because of the lack of therapeutic activity of isoniazid and RIF against MDR-TB. However, little is known about the interactive effects between STR- and FLQ-resistant mutations in mycobacteria.

In this study, with the aim to explore the interaction between STR- and FLQ-resistant mutations, *Mycobacterium smegmatis* was used as a model to investigate the epistasis between mutations conferring resistance to STR and FLQ and the data obtained were then compared with the frequency of STR--FLQ dual-resistant gene mutations in clinical *Mycobacterium tuberculosis* isolates.

Materials and methods
=====================

Bacterial strains and culture conditions
----------------------------------------

The wild-type *M. smegmatis* strain mc[@b2-idr-11-431]155 was used as the starting strain for the screening of drug-resistant strains and the reference for the competitive fitness experiments. The mycobacteria were cultured in Middlebrook 7H9 broth supplemented with 0.05% Tween 80 (7H9-Tw). Bacteria were cultured at 37°C with shaking at 180 rpm.

Microplate-based growth assay for minimal inhibitory concentration (MIC) determination
--------------------------------------------------------------------------------------

MIC determination was accomplished as previously described with minor modifications.[@b11-idr-11-431] *M. smegmatis* was shaken at 37°C in 7H9-Tw till reaching optical density (OD~600~) \~0.8. The cells were spun down, washed twice with 7H9-Tw, and diluted by 100-fold in 7H9-Tw. A total of 200 µL of each culture was placed in a 96-well clear bottom plate. After 4 days of incubation at 37°C, OD was measured from the bottom of the well in a plate reader (Bio-Tek Instruments Inc., Winooski, VT, USA). Growth inhibition was calculated from the following formula: $$\text{Percent~OD}_{600} = \frac{\text{Bacteria~and~Compound~}(B + C) - \text{Media~Only~}(M)}{\text{Bacteria~}(B) - \text{Media~Only~}(M)} \times 100$$with media only (M) being OD in no growth control wells and bacteria (B) being OD in controls without added antibiotic. The MIC~90~ was defined as the concentration of antibiotic that caused 90% growth inhibition. Each antibiotic was tested with biological and technical duplicates for every experiment.[@b12-idr-11-431]

Screening for single- and dual-resistant *M. smegmatis* mutants
---------------------------------------------------------------

Single STR- and FLQ-resistant *M. smegmatis* mutants were screened as follows. The wild-type *M. smegmatis* was cultured till the end of log phase, and 200 µL of bacterial culture was plated onto the minimum of 20--30 plates (or more) of 7H9 agar media containing 16 µg/mL of STR for the isolation of STR-resistant colonies and 10 µg/mL of FLQ (fluoroquinolonic acid) for the isolation of FLQ-resistant colonies. The plates were incubated for 3--5 days at 37°C until colonies became visible. Colonies from these plates were picked and sub-cultured in antibiotic-free Middlebrook 7H9 broth, and the bacteria were cultured to the end of log phase for usage. STR-resistant strains with different *rpsL* mutants screened above were used subsequently to obtain STR--FLQ dual-resistant strains by culturing in 7H9 agar media containing 10 µg/mL of FLQ.

Mutation type identification
----------------------------

The resistance-related genes, including *rpsL* for STR and *gyrA* for FLQ, were amplified by polymerase chain reaction (PCR) using DNA extracted from the single- and dual-resistant mutants. The primers used to amplify the whole gene of *rpsL* were 5′-GGT CGG CCC TGG TAT TGTG-3′ and 5′-ACG ACG CTG ACG GGA GAAG-3′. Mutations in the quinolone resistance-determining region (QRDR) of *gyrA* were amplified by primers of 5′-CAT GAG CGT GAT CGT GGG CCG-3′ and 5′-CAG AAC CGT GGG CTC CTG CAC-3′. The 50 µL of PCR mixtures contained 200 µM of dNTP mixture, 0.2 µM of each primer, 50 ng of genomic DNA, and 1.25 U of PrimeSTAR HS DNA Polymerase (Takara Biotechnology, Dalian, China). Amplification consisted of an initial denaturation step at 95°C for 5 min followed by 35 cycles of denaturation at 98°C for 30 s, annealing at 64°C (*rpsL*)/67°C (*gyrA*) for 30 s, and extension at 72°C for 1 min, followed by a final extension at 72°C for 10 min. PCR products were purified and sequenced by Thermo Fisher Scientific (Waltham, MA, USA). The results of sequencing were analyzed by BioEdit using the genome sequence of *M. smegmatis* strain mc[@b2-idr-11-431]155 (NC_018289.1) as the control.

Fitness assay and epistasis measurement
---------------------------------------

The fitness assay was performed as reported previously.[@b7-idr-11-431] The mutants were cultured against the wild-type *M. smegmatis* strain mc[@b2-idr-11-431]155 in antibiotic-free Middlebrook 7H9 media. For each wild-type-mutant pair, between 1 and 4 replicate competition assays were performed. At the start of the experiment, wild-type and mutant cultures were serially diluted to 10^−5^--10^−6^ and plated on nonselective Middlebrook 7H11 media to estimate the baseline colony-forming units (CFU) count in triplicates. About 100 CFU of bacteria/mL from wild-type and mutant cultures were inoculated in 25 mL of Middlebrook 7H9 media in a 1:1 ratio. The competition cultures were incubated at standard conditions on a shaking incubator at 150 rpm. After 72 h, the same competition cultures were serially diluted to 10^−5^--10^−6^ and plated on nonselective Middlebrook 7H11 media, as well as diluted to 10^−4^--10^−6^ and plated on selective Middlebrook 7H11 media to obtain the endpoint CFU counts. The relative fitness of the drug-resistant strain compared with the wild-type and multiplicative model for pairwise epistasis was determined as previously described.[@b7-idr-11-431] Student's *t*-test was used to detect differences in the mean fitness, and the limit for statistical significance was set at *P*=0.05. Test statistics and estimates were based on 1,000 bootstrap replicates. Statistical analysis was performed with STATA SE/10.

Clinical frequency of STR--FLQ-resistant isolates
-------------------------------------------------

Isolated from sputum of pulmonary TB patients in the Public Health Clinical Center of Chengdu, China, from 2010 to 2014, all 213 STR--FLQ dual-resistant *M. tuberculosis* isolates were selected from 2,610 drug-resistant clinical isolates in this study. Genomic DNA was extracted by cetyltrimethyl ammonium bromide (CTAB) and chloroform/isoamyl alcohol extraction method as previously described.[@b13-idr-11-431] Primers 5′-GGCCGACAAACAGAACGT-3′ and 5′-GTTCACCAACTGGGTGAC-3′ were used to amplify the full length of STR resistance-related gene *rpsL*; primers 5′-GGC AAC ACC GAG GTC AAA TC-3′ and 5′-GCC GTC GTA GTT AGG GAT GAA-3′ were used to amplify the QRDR of *gyrA* gene. PCR mixtures were prepared the same as the detection of resistant *M. smegmatis* mutants. PCR program was same as the *gyrA* mutation detection in *M. smegmatis* mutants. PCR products were purified and sequenced by Thermo Fisher Scientific. The results of sequencing were analyzed by BioEdit with the genome sequence of *M. tuberculosis* H37Rv (NC_000962.3) as reference. Additionally, a total of 3,056 whole genome data for clinical *M. tuberculosis* strains were downloaded from The Sequence Read Archive of NCBI (SRA NCBI) database (ERP001072, ERP000192, and SRP018402). The clinical sequence data were aligned with the reference strain H37Rv genome by Bowtie2. The single-nucleotide polymorphisms (SNPs) were identified by Samtools (<https://github.com/samtools/samtools>). Selection of strains with SNPs in *rpsL*/*gyrA* genes and analysis of mutation types and frequency were performed by a Perl script.

Results
=======

Selection of STR- and FLQ-single- and STR--FLQ-double-resistant mutants
-----------------------------------------------------------------------

The MIC of the *M. smegmatis* on STR and FLQ was 0.5 and 2 mg/L, respectively (determined by microplate-based growth assay), the screening of resistant *M. smegmatis* mutants was performed by 16 mg/L of STR and 10 mg/L of FLQ. A total of 60 STR- and 89 FLQ-resistant strains were obtained in single-resistant screening, and 90 STR--FLQ dual-resistant mutant strains were obtained by sequential screening on STR-resistant strains. Mutation types of K43R, K43N, K43M, K43T, K88R, and K88E in *rpsL* and D94A, D94Y, A90V, G88A, D94N, and D94G in *gyrA* were identified in single-resistant mutants, respectively. The amino acid sequence alignment of *rpsL* and *gyrA* showed that those mutation sites were highly conserved among eight *Mycobacterium* spp. In addition, positions of mutations K43 and K88 of *rpsL* were marked as STR interaction site ([Figure 1](#f1-idr-11-431){ref-type="fig"}), found to be highly conserved between *Escherichia coli* and *M. tuberculosis rpsL* ([Figure S1A](#SD1-idr-11-431){ref-type="supplementary-material"}). Accordingly, we further examined the different combination of mutations in *rpsL* and *gyrA* presenting in dual-resistant mutants ([Table 1](#t1-idr-11-431){ref-type="table"}). Most mutation sites of *gyrA* found in STR--FLQ dual-resistant mutants were consistent with those in FLQ single-resistant mutants.

Fitness cost of STR--FLQ-resistant mutants
------------------------------------------

Relative fitness of *M. smegmatis* mutants were obtained by co-cultivation in vitro against their susceptible ancestor. For the STR-resistant mutants, we found that the strains with K43R showed no difference in relative fitness compared with their susceptible ancestor, while K43N, K43M, K43T, and K88E showed a significantly lower relative fitness (*P*\<0.05). Additionally, with the highest relative fitness, K43R mutants presented at the highest frequency (7/15) in STR-screened mutants ([Table 1](#t1-idr-11-431){ref-type="table"}). Interestingly, the strains with K88R mutation showed considerable differences in fitness cost ([Figure 2A](#f2-idr-11-431){ref-type="fig"}). For the FLQ-resistant mutants, all mutation types were detected with no difference in relative fitness compared with their susceptible ancestor ([Figure 2B](#f2-idr-11-431){ref-type="fig"}). No fitness cost was caused by FLQ-resistant mutations in the resistant strains screened. Except strains harboring K43R and K88R mutations, other STR--FLQ dual-resistant strains showed a significant decrease in relative fitness compared with wild strains ([Figure 2C](#f2-idr-11-431){ref-type="fig"}). Significantly negative epistasis was found in the strain with K43M/D94Y, K43M/D94G, and K43T/D94G mutations (*P*\<0.05) ([Table S1](#SD3-idr-11-431){ref-type="supplementary-material"}).

Remarkably, the model of mutations appearing in *rpsL* and *gyrA* in this study ([Figure S1](#SD1-idr-11-431){ref-type="supplementary-material"}) allows to have an insight on the structural evidence of dispensable feature for these mutations. There are 69% identities between *M. tuberculosis* and *E. coli rpsL* ([Figure S2](#SD2-idr-11-431){ref-type="supplementary-material"}). Mutation sites of *M. tuberculosis rpsL* could be seen through the structure of *E. coli rpsL* (Protein Data Bank accession number 5U4I). Indeed, K43 and K88 of *M. tuberculosis rpsL* are located closely in the conformation of *E. coli* 30S ribosomal protein S12 (5U4I as the structure of *E. coli* entire ribosomal complex).[@b14-idr-11-431] Similarly, the G88, A90, and D94 of *M. tuberculosis gyrA*, crucial for its proper function, sit at the interacting area of chain A and chain B of 3IFZ, which is the crystal structure of *M. tuberculosis* DNA gyrase.[@b15-idr-11-431]

Clinical epistasis in STR--FLQ-resistant *M. tuberculosis*
----------------------------------------------------------

Among the 213 STR--FLQ dual-resistant clinical isolates collected, we identified 122 isolates with mutations in both *rpsL* and *gyrA* genes and 25 isolates with no mutations in them. The other 17 and 49 isolates were detected with mutations in *rpsL* and *gyrA*, respectively. Four mutation types, such as K43R (n=107), K88R (n=30), K88T (n=1), and K88M (n=1), were seen in *rpsL*, while eight mutation types, such as D94G (n=72), A90V (n=41), D94A (n=17), S91P (n=12), D94Y (n=15), D94N (n=12), D94H (n=2), and G88C (n=1), were seen in *gyrA* ([Table 2](#t2-idr-11-431){ref-type="table"}). Several mutation types in *rpsL* (K43N, K43M, K43T, and K88E), present in STR-resistant *M. smegmatis* mutants, were not identified in clinical *M. tuberculosis* isolates. Similarly, the *gyrA* mutation present in FLQ-resistant *M. smegmatis* strains (G88A) was not identified in *M. tuberculosis* strains. Among the *M. tuberculosis* strains harboring *rpsL* and *gyrA* dual mutations, the most frequent combinatorial mutation types were K43R/D94G (n=37) and K43R/A90V (n=24) ([Figure 3A](#f3-idr-11-431){ref-type="fig"}). By searching 3,056 *M. tuberculosis* genome sequence in global SRA NCBI database, we found 148 strains with *rpsL* and *gyrA* combinatorial mutations ([Figure 3B](#f3-idr-11-431){ref-type="fig"}). Similar to our local clinical data, only K43R and K88R mutation types were found in *rpsL* in *M. tuberculosis*, with D94G, A90V, D94A, S91P, D94Y, and D94N being the predominant ones (79.7%) in *gyrA*. Based on the information available, K43R and D94G mutations exhibited the highest frequency in *rpsL* and *gyrA*, respectively.

Discussion
==========

The development of drug resistance in *M. tuberculosis* is commonly influenced by different factors, such as the lineages preferentially associated with resistance to multiple drugs,[@b16-idr-11-431] enhanced heterogeneity at low pH,[@b17-idr-11-431] and sub-lethal antibiotic treatment.[@b18-idr-11-431] Epistatic interactions in strains of different genetic background, drug-resistant mutations, and compensatory mutations could play a role in the emergence of drug-resistant *M. tuberculosis*.[@b19-idr-11-431] In our study, significant epistasis was found in mutations occurring in *rpsL* and *gyrA* of mycobacteria.

The genes of *rpsL* and *gyrA* have been widely reported to be related to STR and FLQ resistance in *M. tuberculosis*, respectively.[@b20-idr-11-431] Mutations in the DNA gyrase genes (*gyrA* and *gyrB*) may lead to the resistance to FLQ. However, most of the clinical isolates showed mutations mainly on codons 90, 91, and 94, which are located in the QRDR of *gyrA*. Thus, the FLQ-resistant mutants were analyzed by sequencing the QRDR of *gyrA* in the present study. In our study, 59/60 STR-resistant strains selected from susceptible *M. smegmatis* were identified to harbor the mutations in codon 43 and 88 of *rpsL*, suggesting that the nucleotide change in *rpsL* was the main cause of STR resistance in spontaneous mutation in vitro, which was similar for STR-resistant *M. smegmatis* strains screened in the previous study.[@b21-idr-11-431] However, only 42/89 FLQ-resistant *M. smegmatis* strains were detected with mutations in *gyrA* and this implied that other important mechanisms might exist in the development of resistance to FLQ, for example, the phenotypic resistance to FLQ by mycobacterial mistranslation.[@b22-idr-11-431] In previous report by Borrell et al,[@b7-idr-11-431] only four mutation types were found in *gyrA*, whereas more *gyrA* mutations were detected in our screening, providing a more comprehensive information on their functions. Various combinations of *rpsL* and *gyrA* mutations were detected in dual-resistant *M. smegmatis* screening, suggesting that some kinds of preferences might exist favoring the development of dual-mutations.

It has been generally accepted that the acquisition of drug resistance typically confers a reduction in fitness when the antibiotic is absent.[@b23-idr-11-431] However, drug-resistant-related mutations with low or no fitness cost were reported recently in *M. tuberculosis* and *Salmonella typhi*,[@b24-idr-11-431]--[@b26-idr-11-431] and the evolution of compensatory mutations may further contribute to the spreading of drug-resistant TB disease.[@b27-idr-11-431] In our study, significant fitness differences were detected among *M. smegmatis* strains of different STR-resistant mutations. K43R in *rpsL*, the most important mutation causing STR-R, showed a significant higher fitness than other mutations in *rpsL*. The absence of fitness cost in K43R mutants presumably lead to the increased frequency of occurrence observed for resistant strains harboring this mutation. Therefore, we could observe a dominant (107/139) K43R mutation in clinical STR-resistant *M. tuberculosis* isolates. The strains with other mutations, such as K43M/T/N and K88E, presented a lower relative fitness when compared with the K43R mutant in competition assays with the wild-type strain of *M. smegmatis*. This property could explain the absence of these mutations in the clinical *M. tuberculosis* isolates analyzed. Notably, varied fitness was found in strains harboring K88R mutation, which might result in the changed frequency of K88R, the second highest in clinical STR-resistant mutations. Although the G88C mutation showed a significant decrease in relative fitness reported by Borrell et al,[@b7-idr-11-431] *gyrA* mutations in *M. smegmatis* showed no fitness cost in all six mutation types, including G88A, in our study. Surprisingly, in clinical *gyrA* mutations, D94G/A and A90V contributed \>76% (130/171) in 213 STR--FLQ dual-resistant *M. tuberculosis* isolates, which suggested that the preference of *gyrA* mutations for FLQ-R exists in clinical isolates and the fitness of *gyrA* in *M. smegmatis* might not sufficiently reflect the situation of clinical model. The frequency of mutation types in clinical *M. tuberculosis* genome database showed similar trend to our local clinical detection, supporting this preference existing wildly in clinical cases.

Epistasis between different antibiotic resistance mutations can affect the fitness-related traits and has an important impact on the evolutionary dynamics of a population.[@b28-idr-11-431]--[@b30-idr-11-431] In our study, the relative fitness of STR--FLQ dual-resistant *M. smegmatis* strains showed a low fitness except those with K43R/D94G, K43R/A90V, and K88R/A90V mutations, indicating that the fitness of dual-resistant strains was mainly determined by the mutation type of *rpsL*. High fitness of K43R and K88R always exhibited high relative fitness in STR--FLQ dual-resistant mutations; low fitness K43N/M/T and K88E came with low relative fitness in STR--FLQ dual-resistant mutants with these mutations. The *rpsL*/*gyrA* dual-mutation types, such as K43R/D94G, K43R/A90V, K88R/D94G, and K88R/A90V, also presented with high frequency in clinical *M. tuberculosis* isolates (79/122). Negative epistasis in K43M/D94Y, K43M/D94G, and K43T/D94G of significant lower fitness was found in our study, and this adverse dual mutation was also absent in clinical *M. tuberculosis* isolates. It suggested that epistatic effect between *rpsL* and *gyrA* may affect the preference of mutation type in clinical isolates. Similar to our study, in a household-based case--control study by Salvatore et al,[@b31-idr-11-431] K43R mutation in *rpsL* was less likely to be found in multiple-case households, suggesting a negative epistatic interaction. In the work by Borrell et al,[@b7-idr-11-431] sign-epistasis (when one mutation has the opposite effect in the presence of another mutation) occurred in six *rpoB*/*gyrA* dual-mutation strains with fitness of the double-resistant mutant being higher than at least one of the corresponding single-resistant mutants. It is possible that various epistatic effects exist in different genes, and future research should focus more on the mechanism of negative epistasis between specific mutation types of *rpsL* and *gyrA*.

Conclusion
==========

The fitness of dual-resistant strains was primarily determined by the mutation type of *rpsL*, which was verified by clinical frequency distortion of drug-resistant mutations. Although only one negatively epistatic mutation combination of K43M/D94Y was detected in our study and significant absence of this combination was found in clinical investigation, the further work should be performed to explore the negatively epistatic mutation combination in other anti-TB drugs. Understanding how the resistance conferring mutations interact with negative epistasis could help us optimize the treatment of combined use of drugs and thus reduce the possibility of drug resistance emergence.

Supplementary materials
=======================

###### 

Model of mutations appearing in *rpsL* and *gyrA* in this study.

**Notes:** (**A**) Structure of *Escherichia coli rpsL* (Protein Data Bank accession number 5U4I). The position of K43 residue (yellow) and K88 residue (red) screened in this study was highly conserved between *E. coli* and *Mycobacterium tuberculosis*. (**B**) *M. tuberculosis gyrA* (Protein Data Bank accession number 3IFZ). The position of G88 residue (yellow), A90 residue (red), and D94 residue (cyan) screened in present study is shown. Amino acids were placed in the cartoon structure in dots format using the PyMOL Viewer.

###### 

The alignment of *rpsL* in *M. tuberculosis* and *E. coli*.

###### 

Epistasis (*e*) in mutants resistant to STR and FLQ

  Sample        STR--FLQ resistance   *ε*    SD of *ε*   
  ------------- --------------------- ------ ----------- -------
  Ms_SF16R12    K43R                  A90V   −0.057      0.021
  Ms_SF16R14    K43R                  D94G   0.021       0.020
  Ms_SF16R210   K43N                  D94N   −0.143      0.080
  Ms_SF16R22    K43N                  D94G   −0.127      0.076
  Ms_SF16R262   K43M                  D94A   −0.114      0.052
  Ms_SF16R265   K43M                  D94Y   −0.222      0.054
  Ms_SF16R260   K43M                  D94N   −0.106      0.052
  Ms_SF16R261   K43M                  D94G   −0.352      0.049
  Ms_SF16R18    K43T                  D94N   −0.027      0.015
  Ms_SF16R19    K43T                  A90V   −0.027      0.015
  Ms_SF16R13    K43T                  D94G   −0.055      0.014
  Ms_SF16R204   K88R                  A90V   0.224       0.283
  Ms_SF16R217   K88E                  A90V   −0.072      0.038

**Abbreviations:** FLQ, fluoroquinolones; STR, streptomycin.
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![Functional domain and conservation of *rpsL* (**A**) and *gyrA* (**B**) mutation sites in *Mycobacterium* spp.](idr-11-431Fig1){#f1-idr-11-431}

![Relative fitness of *Mycobacterium smegmatis* mutants.\
**Notes:** (**A**) Relative fitness of STR-resistant *M. smegmatis*. (**B**) Relative fitness of FLQ-resistant *M. smegmatis*. (**C**) Relative fitness of STR and FLQ dual-resistant *M. smegmatis*. Gray bar is for the STR-resistant *M. smegmatis*, turquoise is for FLQ-resistant, and purple is for the STR--FLQ dual-resistant *M. smegmatis*.\
**Abbreviations:** FLQ, fluoroquinolones; STR, streptomycin.](idr-11-431Fig2){#f2-idr-11-431}

![Frequency of dual-mutation of *rpsL* and *gyrA* found in clinical *Mycobacterium tuberculosis* isolates.\
**Notes:** (**A**) Mutation combinations of clinical *M. tuberculosis* isolates from Sichuan. (**B**) Mutation combinations of 3,056 *M. tuberculosis* genome sequence in database.\
**Abbreviation:** MTB, *Mycobacterium tuberculosis*.](idr-11-431Fig3){#f3-idr-11-431}

###### 

Mutation types of single- and dual-resistant *Mycobacterium smegmatis* mutants under the selection of antibiotics

  -----------------------------------------------------------------------------------------------------------------------------------------------
  Resistant type   Screening concentration (mg/L)   Number of isolates   Mutation types
  ---------------- -------------------------------- -------------------- ------------------------------------------------------------------------
  STR-R            16                               60                   *rpsL*: K43R(28), K43M(7), K43N(4), K43T(2), K88E(14),K88R(4), NM(1)

  FLQ-R            10                               89                   *gyrA*: D94A(19), D94Y(9), A90V(10), G88A(2), D94N(1), D94G(1), NM(47)

  STR--FLQ-R       10                               90                   K43R: A90V(16), D94G(2), NM(4)\
                                                                         K43M: D94G(14), D94A(1), D94Y(1), D94N(1), D89N(1), NM(2)\
                                                                         K43N: D94G(9), D94N(1), NM(5)\
                                                                         K43T: D94G(1), D94N(1), A90V(2), NM(5)\
                                                                         K88R: A90V(2), NM(10)\
                                                                         K88E: A90V(2), NM(10)
  -----------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** FLQ, fluoroquinolones; STR, streptomycin.

###### 

Gene mutations in clinical STR- and FLQ-resistant *Mycobacterium tuberculosis* isolates

  Mutation type         *rpsL*         *gyrA*         Number of isolates
  --------------------- -------------- -------------- --------------------
  *rpsL*(K43R)/*gyrA*   aag®agg K43R   gac®ggc D94G   37
  aag®agg K43R          gcg®gtg A90V   24             
  aag®agg K43R          gac®gcc D94A   8              
  aag®agg K43R          tcg®ccg S91P   9              
  aag®agg K43R          gac®tac D94Y   10             
  aag®agg K43R          gac®aac D94N   4              
  aag®agg K43R          gac®aac D94H   2              
  *rpsL*(K88R)/*gyrA*   aag®agg K88R   gac®ggc D94G   11
  aag®agg K88R          gcg®gtg A90V   7              
  aag®agg K88R          gac®gcc D94A   5              
  aag®agg K88R          tcg®ccg S91P   1              
  aag®agg K88R          gac®tac D94Y   1              
  aag®agg K88R          gac®aac D94N   2              
  *rpsL*(K88T)/*gyrA*   aag®acg K88T   gac®ggc D94G   1
  Single mutation       aag®agg K43R   NM             13
  aag®agg K88R          NM             3              
  aag®atg K88M          NM             1              
  NM                    gac®ggc D94G   23             
  NM                    gcg®gtg A90V   10             
  NM                    gac®gcc D94A   3              
  NM                    tcg®ccg S91P   2              
  NM                    gac®tac D94Y   4              
  NM                    gac®aac D94N   6              
  NM                    ggc®tgc G88C   1              
  No mutation           NM             NM             25

**Note:** NM, no mutation detected.
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